This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Pfizer licensed exclusive worldwide development and marketing rights from Guilford Pharmaceuticals (sells pharmaceuticals to hospital and neurology markets) to a class of compounds--NAALADase inhibitors--which have shown potential in Phase I trials as peripheral and central neurodegenerative disease therapeutics. The company is paying Guilford $15mm plus additional considerations for the rights.
R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?